E4A08
A Randomized Phase III Trial of Melphalan and Dexamethasone (Mdex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autoogous Stem-Cell Transplantation.
CALGB 90601
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine,Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.
ECOG E3F05
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Glioma.
Neoadjuvant:
NSABP B-41
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER-2 Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.
DCIS:
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.
NSABP B-47
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophoshamide or Four Cycles of Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive of High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
Metastic:
Novartis CZOL446E2352
CZOL446E2352: A Prospective, Randomized, Double-Blind, Stratified, Multi-Center, 2-Arm Trial of the Continued Efficacy and Safety of Zometa® (every 4 weeks vs. every 12 weeks) in Patients With Documented Bone Metastases From Breast Cancer.
Genentech:TDM4370G/BO21977: (EMILIA)
A Randomized, Multicenter, Phase III, Open-Label Study Of The Efficacy And Safety Of Trastuzumab-Mcc-Dm1 Vs. Capecitabine + Lapatinib In Patients With HER2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy.
ECOG E2108
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer.
SWOG S0518
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) in Advanced,Poor Prognosis Carcinoid Patients.
Protocol, DIAG-09/002-P Pioneer GCC Registry
Non-interventional study collecting data to examine the relationship between the Previstage GCC Colorectal Cancer Staging Test and disease recurrence in patients who have undergone surgical resection of stage I or II colorectal cancer.
Metastatic:
CALGB C80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.
ARQ 197-A-U252
A Randomized, Placebo-Controlled, Phase ½ Study of ARQ 197 in Combination with Irinotecan and Cetuximab in Subjects with Metastatic Colorectal Cancer With Wild-Type KRAS Who have Received Front-Line Systematic Therapy.
GOG 0249
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early Stage Endometrial Carcinoma.
RTOG 0436
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for patients with Esophageal Cancer who are treated without surgery
RTOG 1010
A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adencarcinoma.
RTOG 0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.
RTOG 1008
A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.
Adjuvant:
ECOG E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC).
First Line Metastic:
BSI-201 Lung (ECLIPSE)
Gemcitabine/Carboplatin +/- BSI-201 (PARP-I) 1st Line Advanced Squamous Cell Lung Cancer.
ECOG E3508
A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer
Second Line Metastatic:
MO22097
An Open-Label, Randomized, Phase IIIB Trial Evaluating The Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Lung Cancer (NSCLC) after First-Line Treatment with Bevacizumab Plus A Platinum Doublet-Containing Chemotherapy
CALGB C50303
A Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas.
ECOG E1609
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High- Risk Melanoma.
ECOG E3A06
A Randomized Phase III Trial of Lenalidomide versus Observation Alone in patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.
GOG 0252
A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy I Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #7921).
Non-Metastic:
CALGB 90203
A Randomized Phase III Study of Neo-Adjuvant Docetaxel And Androgen Deprivation prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High-Risk, Clinically Localized Prostate Cancer.
RTOG 0534
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA after Radical Prostatectomy.
First Line
12V-MC-CXAB(b) (SCRI GU75)
Randomized, Multicenter, Open-Label, Active-Controlled, Phase II Study of LY2510924 and Sunitinib versus Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Second Line
CALGB 90802
Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors.
AMGEN 20090344
Prospective Study to Evaluate the Correlation Between Physician-Assesse Febrile Neutropenia (FN) Risk Probability Score and Prediction Tool FN Risk Probability Score for Patients with Non-myloid Malignancies.
ATTRACT
Acute venous thrombosis: Thrombosis Removal With Adjunctive Catheter-Directed Thrombolysis.
DIREG_C_04823 (CANTARISK)
A Prospective, Non-Interventional, Cohort Survey on VTE Risk in Patients Receiving New Chemotherapy for Cancer.
For more information on clinical trials please
contact research@echoassociates.org.
